These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20345926)

  • 1. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
    Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of illness and its predictors for Parkinson's disease in Germany.
    Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
    Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in resource utilization for Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
    J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of illness in a Russian cohort of patients with Parkinson's disease.
    Winter Y; von Campenhausen S; Popov G; Reese JP; Klotsche J; Bötzel K; Gusev E; Oertel WH; Dodel R; Guekht A
    Pharmacoeconomics; 2009; 27(7):571-84. PubMed ID: 19663528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
    Péchevis M; Clarke CE; Vieregge P; Khoshnood B; Deschaseaux-Voinet C; Berdeaux G; Ziegler M;
    Eur J Neurol; 2005 Dec; 12(12):956-63. PubMed ID: 16324089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
    Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
    CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
    Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
    Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
    Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
    Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
    Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
    Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease.
    Bach JP; Riedel O; Klotsche J; Spottke A; Dodel R; Wittchen HU
    J Neurol Sci; 2012 Mar; 314(1-2):41-7. PubMed ID: 22133477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease].
    Dengler I; Leukel N; Meuser T; Jost WH
    Nervenarzt; 2006 Oct; 77(10):1204-9. PubMed ID: 17004081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost of illness and health service patterns in Morbus Parkinson in Austria].
    von Campenhausen S; Winter Y; Gasser J; Seppi K; Reese JP; Pfeiffer KP; Geiger-Gritsch S; Bötzel K; Siebert U; Oertel WH; Dodel R; Poewe W
    Wien Klin Wochenschr; 2009; 121(17-18):574-82. PubMed ID: 19890747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
    Iskedjian M; Einarson TR
    Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of Parkinson's disease in Singapore.
    Zhao YJ; Tan LC; Li SC; Au WL; Seah SH; Lau PN; Luo N; Wee HL
    Eur J Neurol; 2011 Mar; 18(3):519-26. PubMed ID: 20840378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.